CAR T Studies Conducted by the Thoracic Oncology TCE

CAR T-cells are genetically modified white blood cells that have been engineered to specifically attack a patient’s cancer. It is a form of personalized immunotherapy developed at Penn's Abramson Cancer Center that harnesses the power of the immune system to combat cancer. 

The Thoracic Oncology TCE is currently conducting two CAR T-cell studies: One on those with lung adenocarcinoma and another on those with mesothelioma.

Lung Adenocarcinoma CAR T Study

Principal Investigator: Charu Aggarwal, MD, MPH

In this trial, we are targeting the white blood cells (T-cells) to attack the molecule mesothelin which is found at high levels on about one quarter of lung cancer patients and at even higher rates in those whose tumors harbor KRAS mutations.

What is the purpose of the Lung Adenocarcinoma CAR T study?

This is a phase I study to establish safety and feasibility of intravenous administered lentiviral transduced human CAR-T Mesothelin (huCAR-T Meso) cells with or without a drug (cyclophosphamide) to “make room” for the T cells by a process called lymphodepletion.

Am I a candidate for the Lung Adenocarcinoma CAR T study?

You may be eligible for the CAR-T study if you have a histologically confirmed metastatic or recurrent lung adenocarcinoma with or without documented pleural effusion; confirmation of tumor mesothelin expression (less than or equal to 50 percent of tumor cells); and disease progression after at least one prior standard of care chemotherapy for advanced stage disease. Prior therapies against PD-1 or PDL-1 are permissible if less than four weeks from enrollment.

Please see the complete list of inclusion and exclusion criteria on the ClinicalTrials.gov website. The identifier is NCT03054298.

For more information and to learn if you are a candidate, contact the study coordinator, Seth Jeffries, at 215-220-9695 or Seth.Jeffries@uphs.upenn.edu

Mesothelioma CAR T Study

Principal Investigator: Andrew Haas, MD

In this trial, we are targeting specialized white blood cells called T cells to attack the molecule mesothelin which is found at high levels on most mesothelioma tumors.

What is the purpose of the Mesothelioma CAR T study?

This is a Phase I (dose-seeking) study to establish the safety and feasibility of intravenously administered lentiviral transduced CAR-T Mesothelin cells administered with and without a drug (cyclophosphamide) to “make room” for these cells in a dose escalation design in patients with pleural mesothelioma.

This is a phase I study to establish safety and feasibility of intravenous administered lentiviral transduced human CAR-T Mesothelin (huCAR-T Meso) cells with or without a drug (cyclophosphamide) to “make room” for the T cells by a process called lymphodepletion.

Am I a candidate for the Mesothelioma CAR T study?

You may be eligible for the Meso CAR-T study if you have a histologically confirmed epithelial malignant pleural mesothelioma (MPM) with or without a pleural effusion (build up of fluid between the lung and chest wall); and a failure of at least one prior standard of care chemotherapy for MPM.

Please see the complete list of inclusion and exclusion criteria on the ClinicalTrials.gov website. The identifier is NCT02159716.

For more information and to learn if you are a candidate, contact the investigator, Andrew Haas, at 215-662-3202 or Andrew.Haas2@uphs.upenn.edu.


Learn about different kinds of clinical trials

Learn more about CAR T-cell immunotherapy